Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 6/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 6/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 6/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 6/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3879580 | 0.86 | GRIA1 (0.43) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL3873587 | 0.73 | GRIA1 (0.35) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5358301 | 0.70 | GRIA2 (0.43) | GRIA1GRIA2GRIA3GRIA4NPSR1 | |
| SCHEMBL27491409 | 0.61 | GRIA1 (0.38) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5361851 | 0.61 | GRIA2 (0.48) | GRIA1GRIA2GRIA3GRIA4NPSR1 | |
| SCHEMBL27540553 | 0.60 | GRIA1 (0.35) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL27460909 | 0.59 | GRIA1 (0.34) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL27478466 | 0.59 | GRIA1 (0.40) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5354922 | 0.59 | NPSR1 (0.34) | GRIA2NPSR1 | |
| SCHEMBL7084826 | 0.58 | GRIA1 (0.34) | GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476668-B2 | Thiadiazine derivatives and use thereof as positive AMPA receptor modulators | LES LABORATOIRES SERVIER (FR) | 2009-01-13 | — | — | US | disclosed |
| US-20070004709-A1 | Thiadiazine derivatives and use thereof as positive ampa receptor modulators | THE UNIVERSITE DE LIEGE (BE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004709-A1 | Thiadiazine derivatives and use thereof as positive ampa receptor modulators | GRM1, GRM3, GABRA1 | GRIA1 12/4885GRIA2 27/4885GRIA3 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.